TIME: How the inflation reduction act could lower your drug costs
Information about this website: Following the March 2026 merger of Patient Advocate Foundation and the PAN Foundation, this website is now a part of Patient Advocate Foundation and remains active during our website transition.
Where to find information during our transition:
- About the merged organization: uniting.patientadvocate.org
- Financial assistance: totalassist.org
- Additional direct patient services and resources: patientadvocate.org
- Education: panfoundation.org and education.patientadvocate.org
- Clinical trials education: clinicaltrials.panfoundation.org
- Advocacy: npaf.org
- Research: patientinsightinstitute.org
With monthly out-of-pocket costs for his prescriptions exceeding $12,000, for George Valentine, the possibility of monthly and annual limits is exciting. “I really feel helpless, as far as being able to predict and support my out-of-pocket drug costs,” he said of the existing Medicare Part D structure.
The PAN grant recipient was interviewed in an article about the healthcare provisions in the Inflation Reduction Act, which the Senate passed on August 7. Executive Vice President Amy Niles, who leads PAN’s advocacy efforts, was also featured in the piece.